E-Learning

JP Morgan analyst Harlan Sur maintained an Overweight rating on Broadcom Inc (NASDAQ:AVGO) with a price target of $210. Broadcom will report fiscal fourth-quarter 2024 earnings on Thursday. Sur noted a strong demand profile for AI products, continued cyclical recovery in its diversified semiconductor (ex-AI) end markets, and unlocked VMWare revenue synergy. As a result, the analyst expects revenue, earnings, and free cash flow to be better than JP Morgan and consensus expectations (revenues comi

Chinese device and now EV-maker Xiaomi revealed its latest offering in the ultra-competitive Chinese auto market, doubling down on the success it's already achieved with its SU7 EV sedan.

The key drivers of the market growth include technological advancements and a rising geriatric population, among others.

U.S. equities were down at midday, pulled lower by falling tech stocks.

On Sunday, Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs. Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of

Nvidia’s (NVDA) shares fell by almost 3% during mid-day trading on Monday after the Chinese government announced an investigation into the chipmaker. Fellow chipmakers Advanced Micro Devices (AMD) and Marvell (MRVL) also saw their shares fall by 4.4% and 5.2%, respectively.

Omnicom Group (OMC) agreed to acquire Interpublic Group of Cos. (IPG) in an all-stock deal to create

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J

Barington Capital Group and Thor Equities called on Macy's to create a real estate subsidiary and limit its capital expenditures.

“Awe of ‘American exceptionalism’ in markets has now gone too far,” said Ruchir Sharma, chair of Rockefeller International.